ADR Biomedical Holdings Inc. (TYO:3750)

Market Cap	6.92B -15.7%
Revenue (ttm)	101.00M +13.5%
Net Income	-558.00M
EPS	-62.50
Shares Out	8.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,600
Open	790.00
Previous Close	775.00
Day's Range	779.00 - 790.00
52-Week Range	759.00 - 950.00
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About ADR Biomedical Holdings

ADR Biomedical Holdings Inc. engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence; ECCL-50 to treat liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of dis...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 13
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 3750

Financial Performance

In fiscal year 2026, ADR Biomedical Holdings's revenue was 50.00 million, a decrease of -59.02% compared to the previous year's 122.00 million. Losses were -396.00 million, -81.50% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 27, 2026

Data Sources Report a data error